Trial Profile
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Zhongyuan Union Stem Cell Bio-engineering Corporation
- 04 Mar 2019 Status changed from recruiting to completed.
- 02 Dec 2016 New trial record